The Phase 3 clinical trial (NCT05653219) investigating ianalumab for the treatment of primary immune thrombocytopenia completed its primary data collection on June 19, 2025. This significant milestone indicates that all data for the study's primary outcome measures have been gathered. The trial enrolled 152 adult participants to evaluate the drug's efficacy and safety in this specific patient population.

Background

Primary immune thrombocytopenia (ITP) is a chronic autoimmune bleeding disorder characterized by a low platelet count, which can lead to bruising and bleeding. The Phase 3 trial for ianalumab focuses on adult patients with primary ITP who have previously failed first-line treatment with steroids, representing a population with an unmet medical need.

Trial design

The study, identified as NCT05653219 and titled "A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids," is a Phase 3, randomized, placebo-controlled trial. It enrolled 152 adult participants diagnosed with primary immune thrombocytopenia who had not responded to prior steroid treatment. The trial's primary objective is to evaluate the effect of two different doses of ianalumab when added to eltrombopag, compared to placebo in addition to eltrombopag, with the aim of prolonging Time to Treatment Failure (TTF) in this patient group.

What this means

The completion of primary data collection for this Phase 3 trial marks a significant step in the development of ianalumab for primary immune thrombocytopenia. This milestone means that the core data required to assess the drug's effectiveness and safety profile have been gathered and will now undergo analysis. The trial aims to provide critical data on whether ianalumab, when combined with eltrombopag, can offer a new and effective treatment option for patients who have not responded adequately to steroids. Clinicians and patients will eagerly await the full analysis of these data to understand the potential role of ianalumab in managing this challenging and often debilitating condition.

Source

This information regarding the primary completion of the trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05653219 was posted on June 19, 2025, on clinicaltrials.gov.